Increase in the prices of Formulations

1285. CHOWDHARY RAM SEWAK: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 674 given in the Rajya Sabha on the 24th July, 1989 and state;

(a) what is the justification for price in crease of Alupent Tablets, Progyron Amps, Ultralan Ointment, Architol Injection, Calciluvin Syrup and Benadryl Syrup; and

(b) what is the ex-factory cost and MAPE taken on each in the break-up sub mitted to his Ministry ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY); (a) The manufacturers of decontrolled medicines are free to revise the prices.

(b) To the extent available, the information is given in the Statement *[See* Appendix CLIV, Annexure No. 65]

Prices of Dexamethasone Formulations

1286. CHOWDHARY RAM SEWAK: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 2953 given in the Rajya Sabha on 5th Decem ber, 1988 and state:

(a) when the prices of Dexamethasone based formulations fixed on 26th July, 1989 were implemented by M/s. Merind Limited;

(b) what was the price charged by the company for each formulation before implementing the revised price and since whsn it was charged;

(c) what is the overcharged amount worked out and upto what period;

(d) whether the amount has been worked out on the consumption of bulk drug or sale of formulations;

(e) what is the break-up of amount worked out and how much has been recovered upto 10th May, 1990;

(f) what are the names of the companies who are licensed to produce Dexamethasone and its sales apart from M/s Merind Limited;

(g) what is the stage of manufacture of each and what was the production of each during the last three years, year-wise: and

(h) what is the price fixed for each and when and what were their formulation prices fixed?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S-GURUPADASWAMY): (a) and (b) The requisite information to the extent available would be collected and laid on the Table of the House.

(c) to (e) The entire findings of the Special Team constituted for the purpose of calculating the over charged amount and the subsequent developments are being looked into afresh. M|s. Merind Ltd. have not deposited any amount into the DPEA.

(f) and *(g)* The requisite information to the extent available is given below.

Sl. No.	Name of the Company	State of manufacture	Production in Kgs. during		
			1986-87	1987-88	1988-89
1	M/s. Cadila	Trions (SD-6).			
2	M/s. Lupin	Not producing for the last 5 years.	321.18 (country's total production)	228.00	343.00
3	M/s. T.N. Dadha	Not reporting the production.			

(h) Effective from 10-11-1989, the prices of Dexamethasone Pure and Dexametha-sone 21-Phosphate have been revised to Rs. 92.00 and Rs. 97.00 per gm. respec. tively. However, prices of formulations based on these revised prices are yet to be notified. The details of existing ceiling prices of farmulations based on Dexatha-sone have already been furnished in reply to Rajya Sabha Unstarred Question No. 1629 answered on 26-3-1990.

Prices of Flucort *range* formulations

1287. CHOWDHARY RAM SEWAK: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 2100 given in the Rajya Sabha on the 28th November, 1988 and state:

(a) what is the amount calculated on *suo moto* basis and upto what period on the Flucort range formulations;

(b) whether his Ministry have recovered any amount;

(c) if so, the total amount recovred upto 10th May, 1990;

(d) whether it is a fact that his Ministry fixed the prices of these formulations in 1984;

(e) if so, what were the prices fixed for each formulation;

(f) whether it is also a fact that these prices have not been implementd till today;

(g) what price was being charged for each on 30th April, 1990 and what penal action has been taken against the company for contravention of Drugs Price Control Order;

(h) whether it is a fact that formulations based on the same bulk drug are marketed by certain other organised sector units without price approval; and

(i) if so, what are the names of these companies and what action has been taken against each?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Amounts re-coverable from the manufacturers of Flucort range of formulations have not yet been finalised either on a *suo moto* basis or otherwise.

(b) No, Sir.

(c) Does not arise.

(d) Yes, Sir.

(e) The details of prices fixed for each formulation on 20th June, 1984 are given in the statement. (See below).

(f) *Prima facie* the prices as fixed by the Government were not complied with by the Company under the plea that Flu cort range of formulations are not price controlled.

(g) After the inclusion of Fluncinolone Acetonide in the Drugs (Priecs Control) Order, 1987, the prices of formulations based thereon were fixed on 9th March, 1990. Details of prices being charged by the company as on 30th April, 1990 are being ascertained. The Company was issued shown cause notices on 18th April, 1990 for th alleged violation of the prices fixed on 20th June, 1984. Necessary action would be taken against the company, if they have not complied with the prieef fixed in March, 1990.

(h) and (i) Besides M/s. Lyka M/s. Wockhardt and M/s. CIPLA in the organised sector are the known producers of formulation containing Flucinolone Acetonide. The prices of formulation produced by theSe two companies were also fixed m the 9th March, 1990.